ShEEP request for a Helios CyTOF MS

ShEEP 请求 Helios CyTOF MS

• 批准号: 9363371
• 负责人: Weiming Xia
• 金额: --
• 依托单位: EDITH NOURSE ROGERS MEMORIAL VETERANS HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-01-01 至 2017-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9363371
• 关键词: Alzheimer' s Disease; Amyloid beta-Protein; Biological; Biological Markers; Blood; Blood Cells; Blood specimen; Boston; Brain; Cell surface; Cells; Central Nervous System Diseases; Clinical Research; Coupled; Detection; Disease; Funding; Goals; Health system; Hospitals; Human; Hybrids; Laboratories; Lewy Body Dementia; Metals; Minor; Molecular; Pathologic; Patients; Peripheral; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Play; Principal Investigator; Process; Program Development; Proteins; Proteomics; Research Activity; Research Personnel; Research Support; Role; Sampling Studies; Sheep; Specimen; Steroids; System; Therapeutic; Time; United States National Institutes of Health; Veterans; base; biomarker discovery; chronic traumatic encephalopathy; clinical care; induced pluripotent stem cell; instrument; kinase inhibitor; mass spectrometer; metabolomics; multidisciplinary; research and development; response; secretase

Abstract The Bedford VA hospital requests for fund to acquire the Helios CyTOF time-of-flight atomic Mass Spectrometer (MS), manufactured by Fluidigm. Currently, our hospital MS laboratory is equipped with a Q Exactive hybrid Orbitrap MS, a Quantiva Triple Quadrupole MS, and a QSTAR MS/MS system. The new Helios CyTOF MS will combine cell cytometer, inductively coupled plasma, time-of-flight MS into a single instrument. It is completely different from existing MS instruments. With the addition of Helios CyTOF MS, we will expand core biomarker detection capability at the Bedford VA Hospital Research and Development program. This instrument will play an important role in multi-disciplinary clinical studies that are supported by VA, providing us with an unparalleled ability to phenotypically and functionally profile cells from normal and diseased states. The Helios CyTOF MS will be used for multiple VA funded studies directed by Drs. Xia, Stein and Hanlon (major users), along with other principal investigators (minor users) at the Bedford VA Hospital (Drs. Moo, Morin, Wells, Semenov), Boston VA Health System (Drs. Driver and Rasmusson), and Columbia VA Hospital (Dr. Gu). The Helios CyTOF MS will be used to analyze a large variety of biological samples for studies related to central nervous system disorders. Specifically, it will be used to characterize induced pluripotent stem cells (iPSC) and to understand and facilitate the reprogramming process from peripheral blood mononuclear cells (PBMC) to iPSC. Response to therapeutics will be predicted (Aim 1). The Helios CyTOF will be used to help establish peripheral biomarkers from subjects with chronic traumatic encephalopathy or Lewy Body Dementia and correlate to neuropathological and Near Infrared (NIR) spectra based analysis (Aim 2). Single-cell proteomics obtained by Helios CyTOF will be profiled with metabolomics and lipidomics in blood samples from Alzheimer’s disease (AD) patients (Aim 3). Finally, multiple biomarker studies supported by VA and NIH will be corroborated by single-cell proteomic profiling with Helios CyTOF (Aim 4).

摘要